CN116113431A - 冠状病毒疫苗 - Google Patents

冠状病毒疫苗 Download PDF

Info

Publication number
CN116113431A
CN116113431A CN202180039232.6A CN202180039232A CN116113431A CN 116113431 A CN116113431 A CN 116113431A CN 202180039232 A CN202180039232 A CN 202180039232A CN 116113431 A CN116113431 A CN 116113431A
Authority
CN
China
Prior art keywords
amino acid
seq
polypeptide
acid sequence
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039232.6A
Other languages
English (en)
Chinese (zh)
Inventor
乔纳森·卢克·希尼
斯内哈·维什瓦纳特
乔治·卡内尔
大卫·韦尔斯
马泰奥·弗拉里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dioxinvax Ltd
University of Cambridge
Original Assignee
Dioxinvax Ltd
University of Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004826.0A external-priority patent/GB202004826D0/en
Priority claimed from GBGB2010672.0A external-priority patent/GB202010672D0/en
Priority claimed from GBGB2015775.6A external-priority patent/GB202015775D0/en
Priority claimed from GBGB2101824.7A external-priority patent/GB202101824D0/en
Priority claimed from GBGB2103214.9A external-priority patent/GB202103214D0/en
Application filed by Dioxinvax Ltd, University of Cambridge filed Critical Dioxinvax Ltd
Publication of CN116113431A publication Critical patent/CN116113431A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180039232.6A 2020-04-01 2021-04-01 冠状病毒疫苗 Pending CN116113431A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2004826.0 2020-04-01
GBGB2004826.0A GB202004826D0 (en) 2020-04-01 2020-04-01 Coronavirus vaccines
GBGB2010672.0A GB202010672D0 (en) 2020-07-10 2020-07-10 Coronovirus vaccines
GB2010672.0 2020-07-10
GBGB2015775.6A GB202015775D0 (en) 2020-10-05 2020-10-05 Coronavirus vaccines
GB2015775.6 2020-10-05
GB2101824.7 2021-02-10
GBGB2101824.7A GB202101824D0 (en) 2021-02-10 2021-02-10 Coronavirus vaccines
GB2103214.9 2021-03-08
GBGB2103214.9A GB202103214D0 (en) 2021-03-08 2021-03-08 Coronavirus vaccines
PCT/GB2021/050830 WO2021198706A2 (en) 2020-04-01 2021-04-01 Coronavirus vaccines

Publications (1)

Publication Number Publication Date
CN116113431A true CN116113431A (zh) 2023-05-12

Family

ID=75426636

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039232.6A Pending CN116113431A (zh) 2020-04-01 2021-04-01 冠状病毒疫苗

Country Status (7)

Country Link
US (1) US20240285751A1 (https=)
EP (1) EP4126033A2 (https=)
JP (2) JP2023522156A (https=)
CN (1) CN116113431A (https=)
AU (1) AU2021249525A1 (https=)
CA (1) CA3179038A1 (https=)
WO (1) WO2021198706A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
CN113527444B (zh) * 2020-04-13 2022-12-27 中国科学院微生物研究所 与新型冠状病毒的抗体有效结合的表位
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
US20240293534A1 (en) * 2021-06-14 2024-09-05 Modernatx, Inc. Coronavirus glycosylation variant vaccines
EP4183409A1 (en) * 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
JP2026508394A (ja) 2023-03-03 2026-03-10 ディオシンバックス リミテッド コロナウイルスワクチン
EP4687969A1 (en) * 2023-04-05 2026-02-11 DIOSynVax Ltd Coronavirus vaccines inducing broad immunity against variants
WO2025083402A1 (en) * 2023-10-16 2025-04-24 Diosynvax Ltd Coronavirus vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690336A (zh) * 2012-06-11 2012-09-26 中国科学院武汉病毒研究所 蝙蝠sars样冠状病毒刺突蛋白免疫决定区及制备方法和用途
US20170096455A1 (en) * 2014-03-20 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CN106928326A (zh) * 2015-12-31 2017-07-07 中国科学院动物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
WO2005077103A2 (en) * 2004-02-12 2005-08-25 Regents Of The University Of Colorado Compositions and methods for modification and prevention of sars coronavirus infectivity
CN1884303A (zh) * 2005-06-20 2006-12-27 中国医学科学院基础医学研究所 SARS－CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
US11918643B2 (en) * 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690336A (zh) * 2012-06-11 2012-09-26 中国科学院武汉病毒研究所 蝙蝠sars样冠状病毒刺突蛋白免疫决定区及制备方法和用途
US20170096455A1 (en) * 2014-03-20 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CN106928326A (zh) * 2015-12-31 2017-07-07 中国科学院动物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JINYONG ZHANG等: "Progress and Prospects on Vaccine Development against SARS-CoV-2", 《VACCINES》, vol. 8, no. 2, 29 March 2020 (2020-03-29), pages 1 - 12, XP055822811, DOI: 10.3390/vaccines8020153 *

Also Published As

Publication number Publication date
AU2021249525A1 (en) 2022-12-08
WO2021198706A3 (en) 2021-12-02
JP2025184979A (ja) 2025-12-18
CA3179038A1 (en) 2021-10-07
JP2023522156A (ja) 2023-05-29
EP4126033A2 (en) 2023-02-08
US20240285751A1 (en) 2024-08-29
WO2021198706A2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CN116113431A (zh) 冠状病毒疫苗
CN113185613B (zh) 新型冠状病毒s蛋白及其亚单位疫苗
US6200959B1 (en) Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US9000141B2 (en) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
US20220040284A1 (en) Vaccines and methods
KR20230005962A (ko) 베타코로나바이러스 예방 및 치료요법
US8586056B2 (en) HIV-1 envelope glycoprotein
US20230149530A1 (en) Influenza vaccines
NO311807B1 (no) HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CN115715199A (zh) 冠状病毒疫苗
WO2023057766A1 (en) Influenza vaccines
US20250312437A1 (en) Coronavirus vaccines
WO2023275538A1 (en) Beta-coronavirus vaccines
US20150174239A1 (en) Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine
Wang et al. A novel multi-variant epitope ensemble vaccine against avian leukosis virus subgroup J
US20130287804A1 (en) Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein
CN115044562B (zh) 一种嵌合表达分子佐剂的重组狂犬病病毒及其制备方法与应用
US20250026794A1 (en) Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
US20140037681A1 (en) Hiv-1 envelope glycoprotein
JP2018515074A (ja) インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
WO2025202630A1 (en) Hemorrhagic fever vaccines
AU2016360487B2 (en) Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
CN113227360A (zh) 具有新型流感病毒来源的血凝素蛋白基因的DIs株来源的重组牛痘病毒
CN112521453A (zh) 寨卡病毒优势t细胞表位肽及其在疫苗和诊断中的应用
BR112018010690B1 (pt) Vacinas tetravalentes de vírus da dengue atenuado

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination